Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06175065 · ClinicalTrials.gov registry record · Phase 2
Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
A Phase 2 study of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by ReAlta Life Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT06175065 is a Phase 2 study of Acute Exacerbation of Chronic Obstructive Pulmonary Disease that is active but no longer recruiting, run by ReAlta Life Sciences. The registered enrollment target is 24 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT06175065, a Phase 2 study of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, is active but no longer recruiting, sponsored by ReAlta Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel peptide being developed for the treatment of AECOPD. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of adults with moderate exacerbations of COPD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RLS-0071
Study Locations (4)
Florida
- Site 02 - St. Petersburg
Maryland
- Site 03 - Glen Burnie
Nebraska
- Site 04 - Omaha
Pennsylvania
- Site 01 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2025-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06175065
The ClinicalTrials.gov registry entry for NCT06175065 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReAlta Life Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Exacerbation of Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06175065 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Maryland, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06175065 about?
NCT06175065 is a clinical study titled "Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease". AECOPD is a major cause of hospital admission and mortality. They contribute to long-term decline in lung function, physical capacity, and quality of life (QoL). RLS-0071 is a novel peptide being developed for the treatment of AECOPD. This study is designed to evaluate the safety and tolerability of...
What is the current status of trial NCT06175065?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-01-25. Estimated completion is 2025-06.
What conditions does trial NCT06175065 study?
This clinical trial studies the following conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT06175065?
The interventions under investigation include: Placebo (DRUG), RLS-0071 (DRUG).
Who is sponsoring clinical trial NCT06175065?
This trial is sponsored by ReAlta Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06175065 being conducted?
This trial has 4 study locations across Florida, Maryland, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.